TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe inflammatory and autoimmune diseases as well as transplant rejection, and Inserm Transfert, on behalf of Inserm (French public organization dedicated to human health) and the Nantes University (Nantes, France), announce the signature of a R&D collaboration agreement. This collaboration agreement complements the December 2016 exclusive worldwide licensing agreement pertaining to a new subset of Treg cells originated in one of the Inserm laboratories.
Txcell, inserm ink research pact,car-tregs in transplantation and ms